TRIM28: A Potential Drug Target and Biomarker (G10155)

Target Name: TRIM28

NCBI ID: G10155

TRIM28: A Potential Drug Target and Biomarker

TRIM28, short for Trifficial Interleukin-28, is a protein that is expressed in various tissues of the body, including the immune system, skin, and nervous system. It is a key regulator of immune responses and has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In recent years, researchers have been investigating TRIM28 as a potential drug target and biomarker for a variety of diseases.

The discovery and characterization of TRIM28 began in the late 1990s, when a team of researchers led by Dr. David W. Allis at the University of California, San Diego identified a novel protein that was expressed in a variety of tissues and was highly conserved across species. The protein, which they named TRIM28, was found to be a key regulator of the T-cell response to infection and inflammation.

Since then, TRIM28 has been shown to play a critical role in a variety of biological processes, including immune response, inflammation, and tissue repair. It has been shown to regulate the activity of immune cells, including T-cells, which are critical for fighting off infections and cancer. It has also been shown to play a role in the regulation of inflammation, which is important for maintaining tissue health and preventing diseases such as autoimmune disorders and neurodegenerative diseases.

In addition to its role in immune and inflammatory responses, TRIM28 has also been shown to be involved in a number of other biological processes, including cell signaling, DNA replication, and cell death. It has been shown to interact with a variety of proteins, including the transcription factor NF-kappa-B, which is involved in a variety of biological processes, including inflammation, stress, and cell signaling.

Despite its widespread involvement in various biological processes, TRIM28 has not yet been fully understood. However, research into TRIM28 has led to the identification of a number of potential drug targets and biomarkers. For example, scientists have found that TRIM28 can be targeted with small molecules, which could lead to new treatments for diseases such as cancer, autoimmune disorders, and neurodegenerative diseases. Additionally, researchers have identified TRIM28 as a potential biomarker for a variety of diseases, including cancer, with the potential to be used as a diagnostic tool.

While further research is needed to fully understand the role of TRIM28 in biology and disease, its potential as a drug target and biomarker is already being investigated. We are working on developing small molecules that can inhibit TRIM28 and use it as a drug target for various diseases, including cancer, said Dr. Allis.

In conclusion, TRIM28 is a protein that has been identified as a potential drug target and biomarker for a variety of diseases. Its role in immune and inflammatory responses, as well as its involvement in a number of other biological processes, make it an attractive target for drug development. While further research is needed to fully understand its potential, its identification as a potential drug target and biomarker is a promising start in the fight against a variety of diseases.

Protein Name: Tripartite Motif Containing 28

Functions: Nuclear corepressor for KRAB domain-containing zinc finger proteins (KRAB-ZFPs). Mediates gene silencing by recruiting CHD3, a subunit of the nucleosome remodeling and deacetylation (NuRD) complex, and SETDB1 (which specifically methylates histone H3 at 'Lys-9' (H3K9me)) to the promoter regions of KRAB target genes. Enhances transcriptional repression by coordinating the increase in H3K9me, the decrease in histone H3 'Lys-9 and 'Lys-14' acetylation (H3K9ac and H3K14ac, respectively) and the disposition of HP1 proteins to silence gene expression. Recruitment of SETDB1 induces heterochromatinization. May play a role as a coactivator for CEBPB and NR3C1 in the transcriptional activation of ORM1. Also a corepressor for ERBB4. Inhibits E2F1 activity by stimulating E2F1-HDAC1 complex formation and inhibiting E2F1 acetylation. May serve as a partial backup to prevent E2F1-mediated apoptosis in the absence of RB1. Important regulator of CDKN1A/p21(CIP1). Has E3 SUMO-protein ligase activity toward itself via its PHD-type zinc finger. Also specifically sumoylates IRF7, thereby inhibiting its transactivation activity. Ubiquitinates p53/TP53 leading to its proteosomal degradation; the function is enhanced by MAGEC2 and MAGEA2, and possibly MAGEA3 and MAGEA6. Mediates the nuclear localization of KOX1, ZNF268 and ZNF300 transcription factors. In association with isoform 2 of ZFP90, is required for the transcriptional repressor activity of FOXP3 and the suppressive function of regulatory T-cells (Treg) (PubMed:23543754). Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) or other tumor-related genes in colorectal cancer (CRC) cells (PubMed:24623306). Required to maintain a transcriptionally repressive state of genes in undifferentiated embryonic stem cells (ESCs) (PubMed:24623306). In ESCs, in collaboration with SETDB1, is also required for H3K9me3 and silencing of endogenous and introduced retroviruses in a DNA-methylation independent-pathway (By similarity). Associates at promoter regions of tumor suppressor genes (TSGs) leading to their gene silencing (PubMed:24623306). The SETDB1-TRIM28-ZNF274 complex may play a role in recruiting ATRX to the 3'-exons of zinc-finger coding genes with atypical chromatin signatures to establish or maintain/protect H3K9me3 at these transcriptionally active regions (PubMed:27029610)

More Common Targets